SGCB and hydrops fetalis: (Mitrovic et al., 2011; Reinke et al., 2015)At present, some preclinical and clinical trials are exploring the effects of new oral sGC stimulators such as riociguat, vericiguat, and praliciguat in the CV field, especially on improving symptoms, reducing mortality and hospitalization rate of HF, and lowering biomarkers of HF in patients with HF.